Severe and Uncontrolled Asthma: Tailoring Therapies for Complex Patients (AAN)
Despite multiple FDA-approved biologics, uncertainty remains regarding biomarker interpretation, patient selection, comparative efficacy, and practical implementation. This activity addresses persistent gaps in clinicians’ ability to accurately identify severe and uncontrolled pediatric asthma, distinguish phenotypes and endotypes, and apply guideline-based strategies to tailor biologic therapy. This activity also reviews current GINA guidance, emerging pediatric trial data, and shared decision-making strategies to improve evidence-based treatment selection, reduce exacerbations, and optimize outcomes in children and adolescents with complex asthma.
This program is a collaboration between the American College of Allergy, Asthma & Immunology and the Allergy and Asthma Network (AAN).
Explore other archived clinical webinars here.
Session recorded on March 18, 2026
Speaker: Leonard Bacharier, MD, FACAAI
Price: FREE for members and non-members
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Primary Care Providers
Allied Health Professionals
Learning Objectives
Upon completion of this activity learners should be able to:
1.Define and differentiate severe and uncontrolled pediatric asthma using current GINA and ERS/ATS criteria and describe key asthma phenotypes and Type 2 inflammatory pathways.
2. Evaluate and interpret Type 2 biomarkers to guide selection of biologic therapies in children and adolescents with severe asthma.
3. Apply evidence from pediatric clinical trials to individualize biologic treatment decisions, incorporate shared decision-making, and assess therapeutic response to improve asthma outcomes.
All identified relevant financial relationships with ineligible companies have been mitigated.
Speaker:
Leonard Bacharier, MD, FACAAI
Advisor: Sanofi/Regeneron, AstraZeneca, Kinaset, Excellergy
Speaker: Sanofi/Regeneron
Research: Sanofi/Regeneron, AstraZeneca
Consultant: Sanofi/Regeneron, AstraZeneca
Moderator:
Tonya Nash, AAN Staff
No relevant financial relationships with ineligible companies to disclose
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance

Facebook
X
LinkedIn
Forward